Antonio Chiesi holds M.D. and Ph.D. degrees and served as the founder and CEO of two biotech companies focused on exosome research and exosome based diagnostics: HansaBioMed OU (based in Tallinn, Estonia) and Exosomics Siena SpA (based in Siena, Italy). Before approaching the entrepreneurship experience, he worked for about 20 years at the National Institute of Health (ISS) in Rome, Italy, where he held the position of the Head of Research at the Anti-Tumor Drugs Section, Department of Therapeutic Research and Medicines Evaluation. The breakthrough work in exosome research and tumor markers of the research group led by Professor Stefano Fais at ISS provided the known how and the intellectual property rights on which both companies are based. His research interests are currently focused on the development of immunometric assays for exosome based diagnostics in humans. In both companies, his research teams are working in this field with different focuses and approaches. His further interests include the use of nanomaterials to improve efficiency of exosome-based immunometric assays, development of exosome-based vaccine approaches, as well as using exosomes for delivery of drugs, small molecules, and RNA to target tissues. The group holds a rapidly increasing number of patents in the above-mentioned fields.
Biography Updated on 1 April 2012